arXiv:2412. 17228v4 Announce Type: replace Abstract: Background: Clinical trials are essential to advancing cancer treatments, but fewer than 10% of adults with cancer enroll in therapeutic trials.
arXiv:2606. 17405v1 Announce Type: new Abstract: Clinical decision support AI systems (CDSASs) must adapt to evolving patient conditions in real-time while adhering to strict safety constraints.
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
arXiv:2608.28708v1 Announce Type: cross Abstract: Prospective silent trials provide an important bridge between retrospective validation of artificial intelligence (AI) models and their use in clinic...
OpenMTB‑Audit is an open‑source benchmark that tests large language models on 500 synthetic non‑small cell lung cancer cases, covering five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. The study found that all eight tested LLMs over‑refused Partially Supported recommendations, collapsing labels to achieve high safety scores. A deterministic seven‑module framework, MTB‑AuditAgent, was introduced to reduce over‑refusal to 6.7% and reach 91.2% accuracy, while an oncologist annotation study highlighted disagreement around the boundary between information sufficiency and treatment optimization.
ClinAgent is a conversational system that uses a ReAct-based LLM agent to retrieve and synthesize clinical trial information from multiple sources such as ClinicalTrials.gov, PubMed, and a local dataset. The agent iteratively reasons over user queries, selects appropriate tools, and refines its actions to provide grounded, up-to-date responses in natural language across multi-turn interactions. Evaluation across three phases shows that DeepSeek (thinking mode) excels in planning quality while Gemini 3.0 Flash delivers the highest overall performance and expert ratings, demonstrating the promise of agentic AI for improving clinical trial data access.
arXiv:2607. 08602v1 Announce Type: new Abstract: Hepatocellular carcinoma (HCC) is a common malignancy and a leading cause of cancer-related mortality.
arXiv:2608.28974v1 Announce Type: new Abstract: Clinically relevant oncology information is distributed across heterogeneous, longitudinal documentation, creating substantial abstraction burden and r...
arXiv:2608.22108v1 Announce Type: new Abstract: Breast Cancer Multidisciplinary Team (MDT) meetings manage increasingly complex cases under considerable time pressure, and documentation requirements...
arXiv:2609.32810v2 Announce Type: replace-cross Abstract: Multidisciplinary tumor boards integrate multimodal clinical observations and longitudinal patient histories through specialist discussions,...
arXiv:2610.16175v1 Announce Type: new Abstract: Real-world studies (RWS) analyze routinely collected healthcare data, such as electronic health records and insurance claims, to estimate treatment eff...
The paper introduces ICD-Deepresearch, a workflow that combines foundation models for electronic health records (EHR) and language models with medical search and ICD dictionaries to forecast future ICD codes for upcoming clinical encounters. It evaluates candidate code transitions by linking patient evidence, external clinical relations, and exact code semantics within a fixed top‑K budget, using SparseEHR for initial priors, GPT‑5 for complementary forecasts, and a final selection step that validates, deduplicates, and ranks candidates. The method achieves patient‑averaged precision/recall of 24.60/35.09% on MIMIC‑III and 25.14/48.32% on MIMIC‑IV, with physicians rating 51–68% of its retrieved documents as useful, outperforming standalone GPT‑5 web search and Medical Deep Research.